Chevy Chase Trust Holdings Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,145,434 shares of the biopharmaceutical company’s stock after acquiring an additional 13,451 shares during the period. Chevy Chase Trust Holdings Inc.’s holdings in Gilead Sciences were worth $92,806,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in the business. Welch Investments LLC bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $108,000. Horan Capital Advisors LLC. bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences in the second quarter valued at approximately $147,000. Hanson & Doremus Investment Management lifted its holdings in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Gilead Sciences by 29.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 480 shares in the last quarter. 75.84% of the stock is owned by hedge funds and other institutional investors.
GILD has been the topic of a number of recent research reports. JPMorgan Chase & Co. set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets restated a “hold” rating and issued a $82.00 target price on shares of Gilead Sciences in a report on Friday, October 20th. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their target price for the company from $88.80 to $76.00 in a report on Tuesday, January 30th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price on the stock. in a report on Wednesday, January 17th. Finally, Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $85.58.
Shares of Gilead Sciences, Inc. (GILD) opened at $78.37 on Tuesday. The stock has a market capitalization of $102,350.00, a price-to-earnings ratio of 8.92, a price-to-earnings-growth ratio of -1.80 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the sale, the executive vice president now owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 578,333 shares of company stock valued at $44,100,508. 1.30% of the stock is owned by company insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.